227 related articles for article (PubMed ID: 30122019)
1. [Effect of PD-1 inhibitor Nivolumab on the proliferation and cytotoxicity of anti-CD19 chimeric antigen receptor T cells].
Zhu HB; Deng Q; Zhang R; Jiang YY; Meng JX; Zhao MF; Li YM; Cui R
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):584-588. PubMed ID: 30122019
[No Abstract] [Full Text] [Related]
2. [PD-1 expression, mRNA level and cytotoxicity changes in CD19CAR-T cells].
Pu YD; Wang J; Deng Q; Zhu HB; Jiang YY; Meng JX; Li YM
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):759-763. PubMed ID: 31648479
[No Abstract] [Full Text] [Related]
3. [In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].
Liu MJ; Mu J; Yuan T; Cui R; Meng JX; Jiang YY; Li YM; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):140-145. PubMed ID: 33858045
[No Abstract] [Full Text] [Related]
4. [Effects of glucocorticoids on the proliferation of CD19 CAR-T cells targeting B-cell tumor cell lines].
Deng HB; Liu MJ; Jiang YY; Yuan T; Zhang R; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):747-751. PubMed ID: 34753229
[No Abstract] [Full Text] [Related]
5. [Optimization of CAR-T cell culture system and lentivirus transduction conditions].
Wang H; Pan J; Jiang D; Qu Y; Li Y; Li G; Chu Y; Zhang X; Xu G
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 May; 36(5):390-397. PubMed ID: 32696750
[TBL] [Abstract][Full Text] [Related]
6. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
7. Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor.
Zhang R; Deng Q; Jiang YY; Zhu HB; Wang J; Zhao MF
Oncol Rep; 2019 Jun; 41(6):3455-3463. PubMed ID: 30942469
[TBL] [Abstract][Full Text] [Related]
8. Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells.
Alnabhan R; Gaballa A; Mörk LM; Mattsson J; Uhlin M; Magalhaes I
Cytotherapy; 2018 Jul; 20(7):941-951. PubMed ID: 29859774
[TBL] [Abstract][Full Text] [Related]
9. PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
Moraes Ribeiro E; Secker KA; Nitulescu AM; Schairer R; Keppeler H; Wesle A; Schmid H; Schmitt A; Neuber B; Chmiest D; Podavini S; Märklin M; Klimovich B; Schmitt M; Korkmaz F; Lengerke C; Schneidawind C; Schneidawind D
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296597
[TBL] [Abstract][Full Text] [Related]
10. [Activity comparison of humanized CD19 CAR-T cells with murine CD19 CAR-T on Nalm-6 cells and xenograft tumor model].
Wang J; Mou N; Meng JX; Li X; Jiang YY; Yuan T; Deng Q
Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):827-832. PubMed ID: 34407586
[No Abstract] [Full Text] [Related]
11. [The specific cytotoxicities of chimeric antigen receptor-engineered T cells on different lymphomas].
Zhang R; Deng Q; Sui SN; Jin X; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):842-847. PubMed ID: 29166735
[No Abstract] [Full Text] [Related]
12. Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.
Young PA; Yamada RE; Trinh KR; Vasuthasawat A; De Oliveira S; Yamada DH; Morrison SL; Timmerman JM
J Interferon Cytokine Res; 2018 Jun; 38(6):239-254. PubMed ID: 29920129
[TBL] [Abstract][Full Text] [Related]
13. [Effects of sodium iodide symporter co-expression on proliferation and cytotoxic activity of chimeric antigen receptor T cells
Tian C; Huang P; He Y; Wang L; Peng Z
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jul; 42(7):1062-1068. PubMed ID: 35869771
[TBL] [Abstract][Full Text] [Related]
14. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.
Stroncek DF; Ren J; Lee DW; Tran M; Frodigh SE; Sabatino M; Khuu H; Merchant MS; Mackall CL
Cytotherapy; 2016 Jul; 18(7):893-901. PubMed ID: 27210719
[TBL] [Abstract][Full Text] [Related]
15. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
[TBL] [Abstract][Full Text] [Related]
16. [Construction and evaluation of dual-effect cord blood natural killer cells expressing highaffinity PD-1 and chimeric antigen CD19 receptor].
Zhong H; Zou Q; Liu H; Wang X; DU S; Liang H; Wu Z; Ye J; Zou Q
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Dec; 41(12):1877-1884. PubMed ID: 35012922
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
[No Abstract] [Full Text] [Related]
18. Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo.
Ye X; Liu M; Lv C; Li Y; Chen L; Zhang J; Mu J; Deng Q
Technol Cancer Res Treat; 2022; 21():15330338221133224. PubMed ID: 36254554
[No Abstract] [Full Text] [Related]
19. Basic Procedures for Detection and Cytotoxicity of Chimeric Antigen Receptors.
Mihara K; Yoshida T; Bhattacharyya J
Methods Mol Biol; 2019; 1904():299-306. PubMed ID: 30539476
[TBL] [Abstract][Full Text] [Related]
20. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.
Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J
J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
